Annual Accounts Payable
$2.37 M
-$538.00 K-18.48%
December 31, 2023
Summary
- As of February 7, 2025, TCRX annual accounts payable is $2.37 million, with the most recent change of -$538.00 thousand (-18.48%) on December 31, 2023.
- During the last 3 years, TCRX annual accounts payable has fallen by -$536.00 thousand (-18.42%).
- TCRX annual accounts payable is now -18.48% below its all-time high of $2.91 million, reached on December 31, 2022.
Performance
TCRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$3.65 M
+$537.00 K+17.27%
September 30, 2024
Summary
- As of February 7, 2025, TCRX quarterly accounts payable is $3.65 million, with the most recent change of +$537.00 thousand (+17.27%) on September 30, 2024.
- Over the past year, TCRX quarterly accounts payable has increased by +$451.00 thousand (+14.11%).
- TCRX quarterly accounts payable is now -28.10% below its all-time high of $5.07 million, reached on September 30, 2021.
Performance
TCRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
TCRX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.5% | +14.1% |
| 3 y3 years | -18.4% | +14.1% |
| 5 y5 years | +135.1% | +14.1% |
TCRX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -18.5% | +34.5% | at high | +106.6% |
| 5 y | 5-year | -18.5% | +135.1% | -28.1% | +106.6% |
| alltime | all time | -18.5% | +135.1% | -28.1% | +106.6% |
TScan Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.65 M(+17.3%) |
| Jun 2024 | - | $3.11 M(+46.5%) |
| Mar 2024 | - | $2.12 M(-10.6%) |
| Dec 2023 | $2.37 M(-18.5%) | $2.37 M(-25.7%) |
| Sep 2023 | - | $3.20 M(-5.8%) |
| Jun 2023 | - | $3.39 M(+22.4%) |
| Mar 2023 | - | $2.77 M(-4.8%) |
| Dec 2022 | $2.91 M | $2.91 M(+7.5%) |
| Sep 2022 | - | $2.71 M(-12.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $3.10 M(+7.3%) |
| Mar 2022 | - | $2.89 M(+63.5%) |
| Dec 2021 | $1.76 M(-39.3%) | $1.76 M(-65.2%) |
| Sep 2021 | - | $5.07 M(+43.0%) |
| Jun 2021 | - | $3.55 M(-0.8%) |
| Mar 2021 | - | $3.57 M(+22.8%) |
| Dec 2020 | $2.91 M(+188.1%) | - |
| Dec 2020 | - | $2.91 M |
| Dec 2019 | $1.01 M | - |
FAQ
- What is TScan Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for TScan Therapeutics?
- What is TScan Therapeutics annual accounts payable year-on-year change?
- What is TScan Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for TScan Therapeutics?
- What is TScan Therapeutics quarterly accounts payable year-on-year change?
What is TScan Therapeutics annual accounts payable?
The current annual accounts payable of TCRX is $2.37 M
What is the all time high annual accounts payable for TScan Therapeutics?
TScan Therapeutics all-time high annual accounts payable is $2.91 M
What is TScan Therapeutics annual accounts payable year-on-year change?
Over the past year, TCRX annual accounts payable has changed by -$538.00 K (-18.48%)
What is TScan Therapeutics quarterly accounts payable?
The current quarterly accounts payable of TCRX is $3.65 M
What is the all time high quarterly accounts payable for TScan Therapeutics?
TScan Therapeutics all-time high quarterly accounts payable is $5.07 M
What is TScan Therapeutics quarterly accounts payable year-on-year change?
Over the past year, TCRX quarterly accounts payable has changed by +$451.00 K (+14.11%)